Tech Company Financing Transactions
Poseida Therapeutics Funding Round
Poseida Therapeutics, based in San Diego, secured $142 million from Novartis Venture Fund, Aisling Capital and Boxer Capital.
Transaction Overview
Company Name
Announced On
4/23/2019
Transaction Type
Venture Equity
Amount
$142,000,000
Round
Series C
Investors
Proceeds Purpose
Proceeds purposes were not disclosed.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
9390 Towne Centre Dr. 200
San Diego, CA 92121
USA
San Diego, CA 92121
USA
Phone
Website
Email Address
Overview
Poseida Therapeutics (Nasdaq: PSTX) utilizes best-in-class, proprietary genome editing technologies to develop targeted, life-saving therapeutics in areas of high unmet medical need.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Eric Ostertag
Chief Medical Officer
Matthew Spear
Vice President
Devon Shedlock
VP - Bus. Development
Mark Gergen
VP - Engineering
Martin Giedlin
VP - Finance
Johanna Mylet
VP - Operations
Jennifer Collins
VP - Regulatory Affairs
Debra Gessner
Browse more venture capital transactions:
Prev: 4/23/2019: CleanSpark venture capital transaction
Next: 4/23/2019: Novo Labs venture capital transaction
Share this article
Where The Data Comes From
We report on all VC transactions involving tech companies. VC investment data records on this site are sourced from publicly available VC deal announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs